Instromedix gets Japanese marketing approval:
This article was originally published in Clinica
Executive Summary
The Japanese Ministry of Health and Welfare has approved Instromedix' (US) range of ambulatory cardiac event monitors for sale in Japan. The average hospital stay for cardiac care in Japan is 21 days, compared with seven in the US. At $16,700 million Japan is the third largest market for medtech products after the US and Europe.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.